Related Experiment Video

Updated: Oct 31, 2025

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

3.0K

Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies

Virginia Falvello1, Catherine Van Poznak2

  • 1Department of Internal Medicine, University of Michigan, 1500 East Medical Center Dr, Ann Arbor, MI, 48109, USA.

Current Osteoporosis Reports
|June 30, 2021
PubMed
Abstract

Insights

Recent advancements in bone metastases treatment for solid tumors show that less frequent zoledronic acid dosing maintains efficacy and reduces costs. Combination therapies require careful consideration of bone-targeted agents for safety and effectiveness.

Area of Science:

  • Oncology
  • Radiopharmaceutical Therapy
  • Medical Oncology

Background:

  • Bone metastases significantly impact patient outcomes in solid tumors.
  • Systemic treatments aim to manage skeletal-related events and improve quality of life.
  • Advances in understanding bone metastasis pathophysiology drive therapeutic innovation.

Purpose of the Study:

  • To review novel and impactful discoveries in the systemic treatment of bone metastatic disease in solid tumors.
  • To highlight recent advancements published within the last five years.
  • To synthesize current evidence on therapeutic efficacy and safety.

Main Methods:

  • Literature review of peer-reviewed publications.
  • Focus on studies published within the past five years.
  • Analysis of systemic treatment modalities for bone metastases.

Main Results:

  • Decreased dosing frequency of zoledronic acid maintains efficacy in preventing skeletal-related events for breast and prostate cancer, while reducing costs.
  • Radium-223 demonstrates efficacy in treating metastatic prostate cancer.
  • Combination therapies involving Radium-223 require bone-targeted agents for optimal safety and effectiveness.
  • Cost-effective dosing intervals for zoledronic acid and nuances of radiopharmaceutical-chemotherapy combinations have been clarified.

Conclusions:

  • Optimized dosing strategies for zoledronic acid can improve cost-effectiveness without compromising efficacy.
  • Careful selection of combination therapies, including bone-targeted agents, is crucial for managing bone metastases.
  • Ongoing research continues to refine systemic treatment approaches for bone metastatic disease.
Keywords:
Bone metastasisRadium-223Skeletal-related eventSolid tumorZoledronic acid

More Related Videos

Models of Bone Metastasis08:49

Models of Bone Metastasis

Published on: September 4, 2012

42.5K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

5.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
785
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K